Prolastin c 1,000 MG/20 ML VLS
Ended Awarded
- Contract number
- SPE2DB25FX7Z9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $18,150
Award facts
- Contract value 100% obligated
- $18,149.94 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $18,149.94 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. The contract, issued on September 24, 2025, with an ultimate completion date of October 16, 2025, carries a firm fixed-price structure with no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency under the SPE2DB program, a $500 million vehicle valid through November 2026 that authorizes the issuance of multiple delivery orders for comprehensive pharmaceutical products and medical supplies supporting Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, leveraging its status as a woman-owned small business to compete effectively in government procurement markets. The company's core capabilities include distribution of branded and generic prescription drugs, biologics, and medical consumables to military and federal healthcare systems. Prolastin C, an alpha-1 proteinase inhibitor indicated for chronic therapy in individuals with emphysema due to severe hereditary alpha-1 antitrypsin deficiency, represents the specialized pharmaceutical products that characterize the company's federal contract portfolio.
Quick answers
Who was awarded contract SPE2DB25FX7Z9?
SPE2DB25FX7Z9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 24, 2025.
How much is contract SPE2DB25FX7Z9 worth?
The government has obligated $18,150 on SPE2DB25FX7Z9.
Is contract SPE2DB25FX7Z9 an order under another contract?
Yes. SPE2DB25FX7Z9 is a delivery order under SPE2DB20D9354, an indefinite delivery contract.
Was contract SPE2DB25FX7Z9 competed?
The extent of competition for SPE2DB25FX7Z9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award